Safety Considerations in Recombinant DNA Research with Pathogenic Viruses - Reference Information
   General Biosafety Guidance  
   Introduction to Risk Assessment  
   Wild Type Influenza Viruses  
   Wild Type SARS-CoV  
   Examples of Risk Assessment Templates  
   Examples Risk Assessments - Presentations  
   Recombinant Influenza Virus and SARS-CoV References  
   Occupational Medical Services for Biomedical Research   
 

General Biosafety Guidance  
   NIH Guidelines for Research Involving Recombinant DNA Molecules  
   Biosafety in Microbiological and Biomedical Laboratories 5th edition  
   USDA ARS CSREES ERS NASS Manual- Chapter 9.4.4 Biosafety Level 3 Agriculture (BSL-3Ag)   
   World Health Organization Laboratory Biosafety Manual 3rd edition  
   Health Canada Material Safety Data Sheets  
   American Biological Safety Association  
   American Industrial Hygiene Association  

Top of Page

Introduction to Risk Assessment  
   Slides from Dr. E. Barkley's presentation   
   NIH Guidelines template   

Top of Page

Information and Biosafety Guidance for Wild Type Influenza Viruses  
   Sections from the NIH Guidelines   
   Sections from the BMBL  
   CDC Update on Avian Influenza A (H5N1)   (Aug. 12, 2004)  
   Avian Influenza: USDA Permitting Requirements under 9 CFR 122   (L. A. Thomas presentation)  
   USDA/CDC Select Agent Program: Data Necessary to Consider Select Agent Exclusion Requests Attentuated Strains of Highly Pathogenic Avian Influenza Viruses   
   WHO laboratory biosafety guidelines for handling specimens suspected of containing highly pathogenic avian influenza A/H5 virus  
   WHO Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses   
   Health Canada Biosafety Advisory Highly Pathogenic Avian Influenza   
   United Kingdom Health and Safety Executive Advice on Assessing the Risks of Working with Highly Pathogenic Avian Influenza Virus   
   Avian Influenza Virus Program at the Virginia-Maryland Regional College of Veterinary Medicine  
   Interim CDC-NIH Recommendation for Raising the Biosafety Level for Laboratory Work Involving Noncontemporary Human Influenza (H2N2) Viruses   (May 2005)  
   Revisions to the influenza summary statement for the 5th edition of the BMBL   (Dr. J Katz presentation at 6/2005 RAC meeting)  
   Harmonization of the NIH Guidelines with other federal Guidances: Biological containment for work with noncontemporary strains of influenza (Dr. K. Harris presentation at 6/2005 RAC meeting)  

Top of Page

Biosafety Guidance for Wild Type SARS-CoV  
   WHO biosafety Guidelines for handling of SARS specimens   
   WHO post-outbreak biosafety guidelines for handling of SARS-CoV specimens and cultures   
   WHO Alert, verification, and public health management of SARS in the post-outbreak period   
   United Kingdom Health and Safety Advisory Severe acute respiratory syndrome (SARS)   

Top of Page

Examples of Risk Assessment Templates for Pathogenic Virus Research  
   Influenza viruses   
   Recombinant influenza virus containment   
   Coronaviruses   

Top of Page

Examples of Risk Assessments  
   Slides from Dr. Y. Kawaoka's presentation: H5N1 and 1918 influenza viruses   
   Slides from Dr. A. Garcia-Sastre's presentation: 1918 influenza virus   
   Slide from Dr. R. Webster's presentation: Containment for HPAI research   
   Slides from Dr. R. Baric's presentation: SARS-CoV   

Top of Page

Recombinant Influenza Virus and SARS-CoV References  
   Tumpey, T., et al., (2004) Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus, PNAS 101:3166-3171.   
   Webby, R., and R. Webster, (2003) Are we ready for pandemic influenza? Science 302:1519-1522.   
   Enserink, M., (2004) Tiptoeing around Pandora's box, Science 305: 594-595.   
   Holmes, K., and L. Enjuanes, (2003) The SARS coronavirus: A postgenomic era Science 300: 1377-1378.   
   Yount, B. et al., Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus PNAS 100:12995-13000.   

Top of Page
 


6705 Rockledge Drive, Suite 750, MSC 7985
Bethesda, MD 20892-7985 (For all non-USPS mail, please use ZIP code 20817)
Phone: 301-496-9838, Fax: 301-496-9839
E-mail OBA at oba@od.nih.gov

RDNA329